Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Damoctocog alfa pegol (Primary) ; Efmoroctocog alfa
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Bayer
- 24 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 Aug 2018 Planned End Date changed from 17 Aug 2018 to 28 Sep 2018.
- 03 Jul 2018 Planned End Date changed from 11 Jun 2018 to 17 Aug 2018.